ストックスクリーナーアプリを入手
1.25
5.04%
0.06
アフターアワーズ：
1.24
-0.01
-0.80%
前日終値:
$1.19
開ける：
$1.19
24時間の取引高:
79,081
Relative Volume:
0.49
時価総額：
$19.77M
収益：
-
当期純損益:
$-11.23M
株価収益率:
-1.5731
EPS:
-0.7946
ネットキャッシュフロー:
$-14.83M
1週間 パフォーマンス:
+7.76%
1か月 パフォーマンス:
-0.79%
6か月 パフォーマンス:
-16.67%
1年 パフォーマンス:
+48.54%
1日の値動き範囲:
$1.17
$1.25
1週間の範囲:
$1.1301
$1.2899
52週間の値動き範囲:
$0.7687
$2.35
Allarity Therapeutics Inc Stock (ALLR) Company Profile
名前
Allarity Therapeutics Inc
セクター
電話
401-426-4664
住所
24 SCHOOL ST., 2ND FLOOR, BOSTON
Compare ALLR vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ALLR
Allarity Therapeutics Inc
|
1.25 | 18.82M | 0 | -11.23M | -14.83M | -0.7946 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Allarity Therapeutics Inc Stock (ALLR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-28 | 開始されました | Ascendiant Capital Markets | Buy |
Allarity Therapeutics Inc (ALLR) 最新ニュース
Aug Reactions: Will Allarity Therapeutics Inc stock recover after earningsPortfolio Risk Summary & Long-Term Growth Portfolio Plans - baoquankhu1.vn
Earnings Miss: Can Allarity Therapeutics Inc weather a recessionCEO Change & AI Driven Stock Price Forecasts - baoquankhu1.vn
[PRE 14A] Allarity Therapeutics, Inc. Preliminary Proxy Statement - Stock Titan
ALLR: Ascendiant Capital Maintains Buy Rating, Raises Price Targ - GuruFocus
Allarity Therapeutics, Inc. (ALLR) stock price, news, quote and history - uk.finance.yahoo.com
Allarity Therapeutics Reports 2025 Financial Results, Advances Stenoparib in Ovarian and Lung Cancer with FDA Fast Track Designation - Minichart
Allarity Therapeutics posts $320k revenue, $11.2M net loss and $14.7M year-end cash (2025) - TradingView — Track All Markets
Allarity Therapeutics (NASDAQ: ALLR) cuts 2025 loss to $11.2M and posts first revenue - Stock Titan
ALLR Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Allarity Therapeutics, Inc. (ALLR) Stock Price, News, Quote & History - ca.finance.yahoo.com
TON Strategy Company (VERB) Reports FY2025 Earnings - AlphaStreet
Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress - Investing News Network
Allarity Therapeutics, Inc. (ALLR) Reports FY2025 Earnings - AlphaStreet
Purple Innovation, Inc. (PRPL) Reports Q4 Earnings - AlphaStreet
Allarity Therapeutics reports full year 2025 financial results and corporate progress - marketscreener.com
Market Catalysts: Is Allarity Therapeutics Inc stock forming a cup and handleWeekly Investment Report & High Accuracy Trade Signal Alerts - baoquankhu1.vn
Allarity Therapeutics Reports Full Year 2025 Financial Results And Corporate Progress - TradingView
Cancer drug gets FDA Fast Track as Allarity says cash lasts to 2028 - Stock Titan
Stenoparib push: Allarity Therapeutics (NASDAQ: ALLR) reshapes cancer pipeline - Stock Titan
Allarity Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Short Interest in Allarity Therapeutics, Inc. (NASDAQ:ALLR) Expands By 27.2% - Defense World
Tranche Update on Allarity Therapeutics, Inc.'s Equity Buyback Plan announced on March 3, 2025. - marketscreener.com
Shorts Report: Can Allarity Therapeutics Inc disrupt its industry2026 Market Trends & Consistent Return Strategy Ideas - baoquankhu1.vn
Former Allarity Executive Winnows SEC’s FDA Approval Scheme Suit - Bloomberg Law News
Allarity Therapeutics (ALLR) Projected to Post Quarterly Earnings on Monday - Defense World
Volume Summary: Will Allarity Therapeutics Inc stock recover after earningsDip Buying & Safe Entry Trade Signal Reports - baoquankhu1.vn
Pharma News: Can Allarity Therapeutics Inc expand its profit margins2026 Bull vs Bear & Low Volatility Stock Recommendations - baoquankhu1.vn
Allarity Therapeutics, Inc.: Fundamental Analysis and Financial Ratings | C6D | US0167441049 - marketscreener.com
Aug Spikes: Whats the analyst consensus on Allarity Therapeutics IncGlobal Markets & AI Driven Stock Reports - baoquankhu1.vn
Inflation Data: Can Allarity Therapeutics Inc disrupt its industry2026 Technicals & Technical Entry and Exit Tips - baoquankhu1.vn
MACD Signal: Can Allarity Therapeutics Inc expand its profit marginsTrade Performance Summary & Stock Market Timing Techniques - baoquankhu1.vn
Allarity’s Terminated Breast Cancer Trial Signals Setback for DRP-Guided Chemotherapy - TipRanks
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates - GuruFocus
Big Picture: Is Allarity Therapeutics Inc backed by strong institutional buying2026 Momentum Check & Community Verified Watchlist Alerts - baoquankhu1.vn
Allarity Therapeutics Secures $20 Million Debt Financing to Advance Stenoparib Toward FDA Approval and Extend Cash Runway to 2028 - Minichart
Allarity closes $20M non-convertible debt to fund stenoparib Phase 2 and extend runway - TradingView
Allarity Therapeutics (NASDAQ: ALLR) closes $20M debt to fund trials - Stock Titan
Allarity closes $20M financing for stenoparib advancement - Yahoo Finance
Allarity secures $20M debt financing to extend cash runway By Investing.com - Investing.com South Africa
Allarity Therapeutics, Inc. announced that it has received $20.93 million in funding - marketscreener.com
Allarity Therapeutics, Inc. Closes $20 Million Non-Convertible Debt Financing - marketscreener.com
Allarity secures $20M debt financing to extend cash runway - Investing.com
Allarity Therapeutics Secures $20 Million Structured Note Financing - TipRanks
Allarity Therapeutics Secures $20.9M Notes Financing From Streeterville, With Collateral Agreements - TradingView
Allarity Therapeutics closes $20 million financing to accelerate the advance of stenoparib toward FDA approval and commercialization - marketscreener.com
Allarity Therapeutics (ALLR) enters $20.93M secured note deal with covenants - Stock Titan
Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib ... - Bluefield Daily Telegraph
Allarity Therapeutics Closes $20 Million Financing To Accelerate The Advance Of Stenoparib Toward FDA Approval And Commercialization - TradingView
Allarity Therapeutics Closes $20 Million Financing to - GlobeNewswire
Aug Analyst Calls: What is Allarity Therapeutics Incs 5 year growth outlookJuly 2025 Short Interest & Free Real-Time Market Sentiment Alerts - baoquankhu1.vn
Retail Trends: What are REV Group Incs earnings expectationsJuly 2025 Chart Watch & Real-Time Stock Entry Alerts - baoquankhu1.vn
Allarity Therapeutics Inc (ALLR) 財務データ
収益
当期純利益
現金流量
EPS
2.69%
0.25%
大文字化:
|
ボリューム (24 時間):